Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy.
Int J Gynecol Cancer. 2019 Jan;29(1):60-67. doi: 10.1136/ijgc-2018-000020.
To explore the factors influencing adoption of the sentinel lymph node (SLN) technique for endometrial cancer staging among gynecologic oncologists.
A self-administered, web-based survey was sent via email (April 20 through May 21, 2017) to all members of European Society of Gynecologic Oncologists, International Gynecologic Cancer Society, and Society of Gynecologic Oncologists. Surgical and pathologic practices related to SLN and reasons for not adopting this technique were investigated.
Overall, 489 attending physicians or consultants in gynecologic oncology from 69 countries responded: 201 (41.1%), 118 (24.1%), and 117 (23.9%) from Europe, the USA, and other countries, respectively (10.8% did not report a country). SLN was adopted by 246 (50.3%) respondents, with 93.1% injecting the cervix and 62.6 % using indocyanine green dye. The National Comprehensive Cancer Network SLN algorithm was followed by 160 (65.0%) respondents (USA 74.4%, Europe 55.4%, other countries 71.4%). However, 66.7% completed a backup lymphadenectomy in high-risk patients. When SLN biopsy revealed isolated tumor cells, 13.8% of respondents recommended adjuvant therapy. This percentage increased to 52% if micrometastases were detected. Among the 243 not adopting SLN, 50.2% cited lack of evidence and 45.3% stated that inadequate instrumentation fueled their decisions.
SLN with a cervical injection is gaining widespread acceptance for staging of endometrial cancer among gynecologic oncologists worldwide. Standardization of the surgical approach with the National Comprehensive Care Network algorithm is applied by most users. Management of isolated tumor cells and the role of backup lymphadenectomy for 'high-risk' cases remain areas of investigation.
探讨影响妇科肿瘤医生采用前哨淋巴结(SLN)技术进行子宫内膜癌分期的因素。
2017 年 4 月 20 日至 5 月 21 日,通过电子邮件向欧洲妇科肿瘤学会、国际妇科癌症协会和妇科肿瘤医生协会的所有成员发送了一份自我管理的网络调查。调查了与 SLN 相关的手术和病理实践以及不采用该技术的原因。
共有来自 69 个国家的 489 名妇科肿瘤学主治医生或顾问做出了回应:来自欧洲、美国和其他国家的分别为 201 名(41.1%)、118 名(24.1%)和 117 名(23.9%)(10.8%未报告国家)。246 名(50.3%)受访者采用了 SLN,其中 93.1%的人向宫颈注射,62.6%的人使用吲哚菁绿染料。160 名(65.0%)受访者遵循国家综合癌症网络的 SLN 算法(美国 74.4%、欧洲 55.4%、其他国家 71.4%)。然而,66.7%的人在高危患者中完成了辅助淋巴结切除术。如果 SLN 活检显示孤立肿瘤细胞,13.8%的受访者建议辅助治疗。如果检测到微转移,这一比例增加到 52%。在 243 名不采用 SLN 的受访者中,50.2%的人认为缺乏证据,45.3%的人表示仪器不足是他们做出决定的原因。
在全球范围内,妇科肿瘤医生越来越接受 SLN 联合宫颈注射用于子宫内膜癌分期。大多数用户采用了与国家综合癌症网络算法相匹配的标准化手术方法。孤立肿瘤细胞的处理以及高危病例辅助淋巴结切除术的作用仍然是研究的领域。